- Health Topics
- The Science
- Grants and Training
- News and Events
- About NHLBI
All News
|
Research Feature
A cell-based look at how the body responds to immune threats may one day help researchers find better treatments for this major U.S. killer For more than a decade, researchers have known that a core component of human immune function – called complement – can influence how the body responds to immune threats. Now researchers from the NIH and around...
Showing 10 out of 92 results
|
Research Feature
NIH research continues to evaluate how blood thinners and anti-inflammatory medications may strengthen recovery at different points in the life of the virus W. Keith Hoots, M.D., director of the Division of Blood Disorders and Resources (DBDR) at the National Heart, Lung, and Blood Institute (NHLBI), shares insight into how treatments that break up...
|
Research Feature
Severe blood clotting in patients has sent researchers in search of answers to optimize treatment and recovery As the virus that causes COVID-19 invades cells and replicates its code for infection, the body’s immune response fights back. However, for some people this can lead to extreme blood clotting – which can increase the risk for heart attack...
|
NHLBI in the Press
A clinical research trial with hundreds of participants was stopped early after it became apparent that neither aspirin nor an anti-clotting medication strengthened recovery among patients with COVID-19 who did not require hospitalization.
|
NHLBI in the Press
After reviewing the electronic health records of 72,147 patients with COVID-19, Cleveland Clinic researchers found those who had previously used a steroid-based nasal spray prior to infection were less likely to be hospitalized, receive intensive care, or die prematurely.
|
NHLBI in the Press
To support people of all ages who have experienced the lingering effects of COVID-19, researchers are collecting and analyzing data from patients at different points of infection. This ongoing research and classification of “long COVID” will guide future treatment and prevention strategies.
|
News Release
The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City...
|
Research Feature
When COVID-19 restrictions closed research laboratories across the country, it meant Erik Kimble, M.D.’s hematology and oncology training came to a virtual crawl. Not surprisingly, Kimble, who completed medical school in Mexico at the height of the swine flu pandemic, was overwhelmed yet again with uncertainty. He spent months preparing for his...
|
NHLBI in the Press
A phase 3 trial found using colchicine reduced death and hospitalization rates among adults with COVID-19 recovering at home, but only if they had a positive test result. More research is necessary to assess the benefits of using this anti-inflammatory treatment for moderate COVID-19 cases.
|
NHLBI in the Press
Researchers identified genes and pathways involved in triggering a hyperinflammatory COVID-19 immune response – starting with platelets – and are studying how inhibiting these pathways may alter clinical outcomes for hospitalized patients.
Credit: NIH Image Gallery
|
NHLBI in the Press
A phase 2 study with 59 patients found fostamatinib, a targeted immune therapy used for a rare bleeding disorder, did not result in more adverse outcomes among adults hospitalized for COVID-19 who required assisted breathing support.